One study demonstrated that inhibiting the NF-κB signaling can interrupt EBV latency in nasopharyngeal carcinoma cells by downregulating BamHI-A rightward transcripts (BARTs) expression and inducing lytic cell replication, suggesting that the NF-κB pathway can be a potential target for future treatment of EBV-associated carcinomas [73]. This evidence concerns the gene NFKB1 and carcinoma.